Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Needham & Company LLC from $34.00 to $42.00. They now have a "buy" rating on the stock.
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)